NASDAQ:ALIM Alimera Sciences (ALIM) Stock Price, News & Analysis $5.56 +0.02 (+0.36%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.54▼$5.6350-Day Range$5.52▼$5.6052-Week Range$2.61▼$5.65Volume9.09 million shsAverage Volume295,580 shsMarket Capitalization$291.28 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Alimera Sciences alerts: Email Address Alimera Sciences MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside43.9% Upside$8.00 Price TargetShort InterestHealthy1.28% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.13) to $0.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.00 out of 5 starsMedical Sector539th out of 910 stocksPharmaceutical Preparations Industry248th out of 426 stocks 3.0 Analyst's Opinion Consensus RatingAlimera Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAlimera Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Alimera Sciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.28% of the outstanding shares of Alimera Sciences have been sold short.Short Interest Ratio / Days to CoverAlimera Sciences has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alimera Sciences has recently increased by 3.92%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlimera Sciences does not currently pay a dividend.Dividend GrowthAlimera Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALIM. Previous Next 1.3 News and Social Media Coverage News SentimentAlimera Sciences has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Alimera Sciences this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Alimera Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alimera Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders31.40% of the stock of Alimera Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.83% of the stock of Alimera Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alimera Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alimera Sciences are expected to grow in the coming year, from ($0.13) to $0.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alimera Sciences is -3.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alimera Sciences is -3.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlimera Sciences has a P/B Ratio of 7.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alimera Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Alimera Sciences Stock (NASDAQ:ALIM)Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Read More ALIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALIM Stock News HeadlinesSeptember 6 at 2:11 AM | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Receives New Coverage from Analysts at StockNews.comAugust 30, 2024 | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Coverage Initiated by Analysts at StockNews.comSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 29, 2024 | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Shares Pass Above 200-Day Moving Average of $4.19August 20, 2024 | businesswire.comALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera ...August 9, 2024 | msn.comShould You Invest on Alimera Sciences, Inc. (ALIM) Right Now?August 6, 2024 | globenewswire.comAlimera Sciences Reports Second Quarter 2024 ResultsJuly 27, 2024 | globenewswire.comALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.July 26, 2024 | prnewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIMJuly 25, 2024 | finance.yahoo.comInvesting in Alimera Sciences (NASDAQ:ALIM) a year ago would have delivered you a 68% gainJuly 3, 2024 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIMJuly 2, 2024 | prnewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIMJune 24, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public ShareholdersJune 24, 2024 | investorplace.comWhy Is Alimera Sciences (ALIM) Stock Up 77% Today?June 24, 2024 | globenewswire.comALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI PharmaceuticalsJune 24, 2024 | businesswire.comALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to ShareholdersJune 4, 2024 | globenewswire.comAlimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALIM CUSIPN/A CIK1267602 Webwww.alimerasciences.com Phone(678) 990-5740Fax678-990-5744Employees150Year Founded2003Price Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+43.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,130,000.00 Net Margins-14.74% Pretax Margin-14.76% Return on Equity-33.70% Return on Assets-9.63% Debt Debt-to-Equity Ratio1.80 Current Ratio2.79 Quick Ratio2.62 Sales & Book Value Annual Sales$99.68 million Price / Sales2.92 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book7.83Miscellaneous Outstanding Shares52,389,000Free Float35,939,000Market Cap$291.28 million OptionableOptionable Beta1.25 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Richard S. Eiswirth Jr. (Age 56)CEO & Director Comp: $949.27kMr. Jason Werner (Age 46)Chief Operating Officer Comp: $225.66kDr. Philip Ashman Ph.D. (Age 59)President of International Operations Comp: $516.98kMr. David R. Holland (Age 60)Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets Comp: $413.5kMr. Elliot Maltz CPA (Age 39)CFO & Treasurer Christopher S. VisickVP, General Counsel & SecretaryDr. David Dyer M.D.Chief Retina SpecialistMr. Todd Michael Wood (Age 55)President of U.S. Operations More ExecutivesKey CompetitorsDay One BiopharmaceuticalsNASDAQ:DAWNTango TherapeuticsNASDAQ:TNGXProthenaNASDAQ:PRTAGyre TherapeuticsNASDAQ:GYRETyra BiosciencesNASDAQ:TYRAView All CompetitorsInsiders & InstitutionsStonepine Capital Management LLCSold 539,256 shares on 8/21/2024Ownership: 6.703%Glazer Capital LLCBought 551,533 shares on 8/14/2024Ownership: 1.053%Gabelli Funds LLCBought 108,000 shares on 8/14/2024Ownership: 0.206%Renaissance Technologies LLCBought 6,900 shares on 8/9/2024Ownership: 0.347%Rhumbline AdvisersBought 20,394 shares on 8/1/2024Ownership: 0.039%View All Insider TransactionsView All Institutional Transactions ALIM Stock Analysis - Frequently Asked Questions How have ALIM shares performed this year? Alimera Sciences' stock was trading at $4.32 at the start of the year. Since then, ALIM shares have increased by 28.7% and is now trading at $5.56. View the best growth stocks for 2024 here. How were Alimera Sciences' earnings last quarter? Alimera Sciences, Inc. (NASDAQ:ALIM) posted its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.02. The biopharmaceutical company had revenue of $27 million for the quarter, compared to analysts' expectations of $25.76 million. Alimera Sciences had a negative net margin of 14.74% and a negative trailing twelve-month return on equity of 33.70%. When did Alimera Sciences' stock split? Alimera Sciences shares reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Rick Eiswirth's approval rating as Alimera Sciences' CEO? 2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Alimera Sciences' major shareholders? Top institutional investors of Alimera Sciences include Stonepine Capital Management LLC (6.70%), Glazer Capital LLC (1.05%), Renaissance Technologies LLC (0.35%) and Deltec Asset Management LLC (0.24%). Insiders that own company stock include Caligan Partners Lp, Adam Morgan, Alto Investors Lp Palo, Stanley Morgan, John Philip Jones, Richard S Eiswirth Jr and James R Largent. View institutional ownership trends. How do I buy shares of Alimera Sciences? Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and AngloGold Ashanti (AU). This page (NASDAQ:ALIM) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alimera Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALIM Stock Alerts